U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07761923) titled 'Preserving Muscle Mass During Incretin-Induced Weight Loss' on July 30.
Brief Summary: Treatment with appetite suppressant drugs, including incretin-based receptor agonists, generally leads to clinically meaningful weight loss and reduced cardiometabolic risk. However, weight loss may include not only loss of adipose tissue but also loss of skeletal muscle mass, which ultimately may impair physical function and metabolic health.
Resistance training is an effective strategy to maintain or increase skeletal muscle mass during weight loss, but its effects during treatment with appetite suppressant obesity medications have been studied...